LncRNA CARMN Affects Hepatocellular Carcinoma Prognosis by Regulating the miR-192-5p/LOXL2 Axis

Table 1

Correlation between LOXL2 and different clinicopathological features.

Characteristic	Low-expression of LOXL2	High-expression of LOXL2	p
n	187	187
Age, n (%)			0.107
≤ 60	80 (21.4%)	97 (26%)
> 60	106 (28.4%)	90 (24.1%)
Gender, (%)			0.027
Female	50 (13.4%)	71 (19%)
Male	137 (36.6%)	116 (31%)
Race, (%)			0.188
Asian	81 (22.4%)	79 (21.8%)
Black or African American	12 (3.3%)	5 (1.4%)
White	88 (24.3%)	97 (26.8%)
T stage, (%)			0.013
T1	101 (27.2%)	82 (22.1%)
T2	49 (13.2%)	46 (12.4%)
T3	33 (8.9%)	47 (12.7%)
T4	2 (0.5%)	11 (3%)
N stage, (%)			0.125
N0	121 (46.9%)	133 (51.6%)
N1	0 (0%)	4 (1.6%)
M stage, (%)			1.000
M0	130 (47.8%)	138 (50.7%)
M1	2 (0.7%)	2 (0.7%)
Pathologic stage, (%)			0.121
Stage I	96 (27.4%)	77 (22%)
Stage II	44 (12.6%)	43 (12.3%)
Stage III	34 (9.7%)	51 (14.6%)
Stage IV	2 (0.6%)	3 (0.9%)
Histologic grade, (%)			0.029
G1	37 (10%)	18 (4.9%)
G2	87 (23.6%)	91 (24.7%)
G3	54 (14.6%)	70 (19%)
G4	7 (1.9%)	5 (1.4%)
Tumor status, (%)			0.305
Tumor free	106 (29.9%)	96 (27%)
With tumor	71 (20%)	82 (23.1%)